NCT06391918 2026-03-13
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
GenVivo, Inc.
Phase 1 Terminated
Clinical Trials
6 trialsNCT05011058 2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2 Terminated
NCT05166577 2025-03-12
Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC
Viracta Therapeutics, Inc.
Phase 1 Terminated
NCT06302140 2025-01-20
A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers
Viracta Therapeutics, Inc.
Phase 1 Terminated
NCT00917826 2011-08-01
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
HemaQuest Pharmaceuticals Inc.
Phase 2 Terminated
NCT00992732 2011-08-01
Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders
HemaQuest Pharmaceuticals Inc.
Phase 2 Terminated